| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc779fa383ceb7941d1b8e54a5ff6527 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-568
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-568
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 |
| filingDate |
2010-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd99e87ccac998382dc19e1bcffbebae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68805ebb7a93cb7cfbfefb03b5c5dff0 |
| publicationDate |
2018-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2685313-T3 |
| titleOfInvention |
Transdermal pharmaceutical compositions comprising active agents |
| abstract |
A pharmaceutical sustained release composition for topical administration to a skin surface comprising: - a pharmaceutically active agent comprising one or more steroids; - 2% ethyl oleate; - Water; - a C2-C6 -2% monoalcohol of oleic acid; - 0.05% to 5% by weight of a gelling agent; and - 5% propylene glycol wherein the weight: weight ratio of the fatty acid ester in the composition to the total active agent in said composition is at least 4: 1 (fatty acid ester: active agent), preferably ranges from 4: 1 to 20: 1. |
| priorityDate |
2009-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |